HAYWARD, Calif., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel ...

HAYWARD, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel ...

HAYWARD, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel ...

Benitec Biopharma (BNTC), a clinical-stage biotech firm, stands at the forefront of gene therapy, making notable strides in developing treatments for chronic and life-threatening conditions, ...

Axovant Sciences has licensed exclusive rights to Benitec Biopharma’s preclinical gene therapy for oculopharyngeal muscular dystrophy (OPMD), set to enter the clinic next year, and five additional ...

Benitec Biopharma, an Australia-based drug developer, has received the FDA’s Orphan Drug designation for BB-301, an investigational drug for the treatment of oculopharyngeal muscular dystrophy.

Oculopharyngeal muscular dystrophy (OPMD) is a rare inherited disorder that causes weakness in the eye and throat muscles. It may lead to drooping eyelids and swallowing difficulties. Muscular ...

Sheba Medical Center in Ramat Gan on Wednesday announced the opening of a specialized clinic for Bukharan Jews with oculopharyngeal muscular dystrophy (OPMD), a genetic disease. The clinic, which is ...

Benitec Biopharma Inc. (NASDAQ:BNTC) shares soared 20% on Monday after the biotech company announced positive interim results from its ongoing Phase 1b/2a clinical trial of BB-301 and confirmed that ...

Benitec Biopharma develops genetic therapies using its proprietary ddRNAi platform. BB-301, which targets OPMD, has shown promising interim trial results. Despite promising early data, BNTC's ...